CTLA4 and lung cancer: Thus, modulating the immune response by targeting PD-1, PD-L1 or CTLA-4 in lung cancer might cause varying effects in the normal tissue, depending on the time point (acute versus chronic) of application, especially in a setting where ICI is given after radiotherapy of the thoracic region.